Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7901–7950 of 18652
Mark Lumpkin, Jr. ceased to serve as the Executive Vice President and Chief Financial Officer of the Company
Pursuant to the Engagement Agreement, Arkady A. Goldinstein will be appointed as the interim Chief Financial Officer of the Company, effective November 1, 2023.
On October 31, 2023, Ms. Christina J. Cook, who has served as the Chief Financial Officer of Arcimoto, Inc. (the “Company”), notified the Company of her decision to resign from her position, effective October 31, 2023.
On November 3, 2023, the Company’s board of directors determined that upon Ms. Cook’s resignation, Mr. Christopher Dawson, the Company’s current Chief Executive Officer, will serve as the Company’s interim Chief Financial Officer and will assume the roles of principal financial officer and principal accounting officer.
On October 30, 2023, Ms. Wei Li Leong, the Chief Financial Officer (“CFO”), tendered her resignation letter to BioNexus Gene Lab Corp. (the “Company”) from her position at the Company.
Effective October 31, 2023 Susan M. Villare resigned as the Chief Financial Officer of MariMed Inc.
The Board of Directors has appointed Jon R. Levine, the Company's President and Chief Executive Officer, as the Company's Interim Chief Financial Officer
On November 3, 2023, David P. Willaims advised Chemed Corporation (the “Company”) that he intends to retire effective December 31, 2023 as Executive Vice President and Chief Financial Officer of the Company.
the Board has appointed Bruce N. Rogers, Ph.D., the Company’s President, as the Company’s interim principal executive officer until Dr. Tipirneni’s return.
Praveen P. Tipirneni, M.D., the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), is taking a temporary medical leave of absence from his role as Chief Executive Officer.
On November 1st, 2023, the board of directors of ConneXionONE Corp. (the "Company") appointed Tingyu (Christine) Chang as the Chief Executive Officer ("CEO") of the Company
this appointment signifies the departure of the former CEO, Chris Chang, who remains a director.
In connection with the previously announced departure of Mr. Scott Sutton, President, Chief Executive Officer and Chairman of the Board of Olin Corporation (the “Company”), which is expected to occur in the first half of 2024, on October 30, 2023, the Company and Mr. Sutton entered into a transition agreement (the “Transition Agreement”).
On November 1, 2023, MSP Recovery, Inc. d/b/a LifeWallet’s (the “Company” or “LifeWallet”) Board of Directors (the “Board”) appointed Francisco Rivas-Vásquez, C.P.A., as the Company’s Chief Financial Officer (“CFO”) and principal financial officer.
On October 30, 2023, the Company announced that John Chen, Executive Chair of the Board of Directors (the “Board”) and Chief Executive Officer of BlackBerry Limited (the “Company”), will retire from his roles at the Company effective November 4, 2023.
the Company announced that Richard (Dick) Lynch, 75, will succeed Mr. Chen as Chair of the Board and will also serve as Interim Chief Executive Officer while BlackBerry completes its search for a permanent Chief Executive Officer.
Nassim Usman, Ph.D., Catalyst’s President and Chief Executive Officer, ceased to be an officer of Gyre
Seline Miller, Catalyst’s Interim Chief Financial Officer, ceased to be an officer of Gyre
The Board appointed Kirk Pressley to succeed Mr. Foshee as Chief Financial Officer following Mr. Foshee’s retirement.
On November 1, 2023, William “Bud” Foshee, Chief Financial Officer of ServisFirst Bancshares, Inc. (“ServisFirst”), notified the Board of Directors (“Board”) of ServisFirst that he will retire from the position of Chief Financial Officer effective after the filing of the Form 10-K in February of 2024.
On October 31, 2023, each of (i) Mr. Jasper Bos and (ii) Mr. Cyril Lesser resigned as Chief Executive Officer and Chief Financial Officer, respectively, of the Company, effective on October 31, 2023 upon the completion of the Business Combination.
On October 31, 2023, each of (i) Mr. Jasper Bos and (ii) Mr. Cyril Lesser resigned as Chief Executive Officer and Chief Financial Officer, respectively, of the Company, effective on October 31, 2023 upon the completion of the Business Combination.
Mr. Robitaille will continue to serve as an executive officer of the Company until November 17, 2023;
On October 29, 2023, Adrian Adams gave notice of his resignation from his position as Chairman of the Board and as President and Chief Executive Officer of Impel Pharmaceuticals Inc. (the “ Company ”) effective November 4, 2023.
The Board of Directors of the Company intends to appoint Leonard S. Paolillo as Interim President and Chief Executive Officer effective upon Mr. Adams’s resignation.
the Board has appointed Maria Hollandsworth as interim Chief Executive Officer and President of the Company (“ Interim CEO ”), effective as of November 4, 2023.
On November 2, 2023, El Pollo Loco Holdings, Inc. (the “ Company ”) announced that Laurance Roberts, the Company’s Chief Executive Officer and President, is leaving his position as Chief Executive Officer and President and as a member of the Board of Directors of the Company (the “ Board ”), effective as of the close of business on November 3, 2023
On November 2, 2023, Silk Road Medical, Inc. (the “Company”) announced the appointment of Charles (Chas) McKhann as Chief Executive Officer (“CEO”) and a director of the Company, effective immediately.
Mr. McKhann will succeed Erica J. Rogers, who is retiring, effective November 2, 2023, and has served on the Company’s Board of Directors and as President and Chief Executive Officer for over 11 years.
The Executive Committee of the Board of Directors of the Company (the “Committee”) has appointed David Wheeler, the Company’s current President, as Interim CEO.
Steven B. Treadwell provided notice of his resignation as Chief Executive Officer (“CEO”) of Silver Star Properties REIT, Inc. (the “Company”), effective October 27, 2023.
Mr. Sauve is the Chief Executive Officer of the Company post Business Combination.
Mr. Jensen also resigned as Chief Executive Officer of the Company
The Company has named Phillip Sawarynski as Mr. Barnes's successor in that role.
appointed Bradford J. Helgeson as Executive Vice President and Chief Financial Officer of the Company, effective November 6, 2023.
Izzy Martins, currently serving as EVP Americas of the Company, will assume the role of EVP & Chief Financial Officer of the Company, effective January 1, 2024.
Leagh E. Turner, co-Chief Executive Officer of Ceridian HCM Holding Inc. (the “Company”) notified the Company of her intent to resign as co-Chief Executive Officer and as a member of the Board of Directors of the Company effective on November 10, 2023.
David D. Ossip, Chair of the Board and co-Chief Executive Officer of the Company, will become sole Chief Executive Officer of the Company.
On November 1, 2023, Eldron C. Blackwell was appointed as the Company's Chief Financial Officer, Senior Vice President and Treasurer, effective January 1, 2024.
On November 1, 2023, David J. Bryant, Chief Financial Officer, Senior Vice President and Treasurer, informed the Company of his intention to retire effective December 31, 2023.
On November 1, 2023, the Board appointed Craig R. Jalbert, age 61, as the Company’s President, Treasurer, Corporate Secretary, effective as of 12:00 a.m. on November 2, 2023, and sole member of the Board, effective immediately.
On November 1, 2023, in connection with the Assignment (as defined below), William R. Hinshaw, Jr. and Paul Fehlner were each notified by the Company of termination of their positions as President and Chief Executive Officer and Senior Vice President, Chief Legal Officer and Corporate Secretary, respectively, effective as of 11:59 p.m. on November 1, 2023.
On October 30 , 2023, the Board of Directors (the “Board” ) of Ocuphire Pharma, Inc. (the “Company” ) appointed Dr. George Magrath, age 39, as the Company’s Chief Executive Officer, effective as of November 1, 2023.
On October 30, 2023, the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Chief Business Officer.
Reginald Seeto, MBBS, the President and Chief Executive Officer of CareDx, Inc. (the “Company”), resigned from the Company.
appointed Jamie Miller as the Company's Executive Vice President, Chief Financial Officer, effective November 6, 2023.
the Board appointed Mr. Jeremy Frommer as the Chief Financial Officer of the Company, effective October 16, 2023.
the Board determined it was in the best interest of the Company to accept Mr. Pickens' resignation and to continue his engagement with the Company as a finance and accounting consultant.
On November 1, 2023, the Company announced that Elizabeth Howe, 53, will join the Company and become Executive Vice President and Chief Financial Officer on November 8, 2023.
On October 30, 2023, Arthur Chadwick, Executive Vice President and Chief Financial Officer of the Company, notified us of his decision to retire and resign from all of his officer positions with the Company and all of its subsidiaries, effective November 7, 2023
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.